VRTX · CIK 0000875320 · FY2025 live · 2025-12-31
VERTEX PHARMACEUTICALS INC / MA
View as
Model
Classic Z
FY2025
3.69
Zone
Safe
Prior
—
Market DD
—
1y PD
—
3.69
Z″ 7.50
Score 3.69 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.291.2 × = 0.34X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
0.531.4 × = 0.74X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
0.163.3 × = 0.54X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
2.680.6 × = 1.61X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.471 × = 0.47
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings.
Meridian Rank
88.55
0–100 · Classic Z family
Book standing
85
Year change
—
Market PD
—
O-score
98
Events on this name
Same published rows as Today.
Approaching grey
watch · 41
- Live score: — → 3.69
- Cut: — → 1.80
Overview
rule-v1
VERTEX PHARMACEUTICALS INC / MA is on classic Z at 3.69 (safe) for FY2025, from an SEC 10-K. Book equity / liabilities is the line that sets the print. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers. Buybacks can send retained earnings negative at otherwise healthy issuers. X4 is book equity.
Book screen Safe; market PD —. Market PD has not been priced on this name.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 87th percentile in Healthcare.
Filing line items
Current assets
$11.2B
Total assets
$25.6B
Current liabilities
$3.9B
Total liabilities
$7.0B
Working capital
$7.3B
Retained earnings
$13.6B
EBIT
$4.2B
Total sales
$12.0B
Book equity
$18.7B
Accession 0000875320-26-000056. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-12-31). Classic Z is the live score. View as is a display overlay. X4 is book equity. Pulled 13 Sept 2026.